“The rate of sustained MG-ADL improvement in the first cycle in antibody-positive patients was 31.3% (20 of 64) in the placebo group vs 58.2% (39 of 67) in the batoclimab group,” the authors ...

Ivermectin Tablets, 3 mg brand and generic products, had U.S. sales of approximately $20M MAT for the twelve months ending in September 2024 according to IQVIA.